相关实验视频

Updated: May 7, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

治疗早期梅克尔细胞癌的有效性和安全性:随机和非随机研究的系统审查和元分析

Yves Paul Vincent Mbous¹, Rowida Mohamed², Usha Sambamoorthi^1,3

¹School of Pharmacy, Department of Pharmaceutical Systems and Policy, Robert C. Byrd Health Sciences Center [North], West Virginia University, Morgantown, West Virginia, USA.

Cancer medicine

|January 3, 2025

概括

辅助放射治疗 (RTx) 改善了存活率,并减少了早期梅克尔细胞癌 (MCC) 的复发,当与手术 (SRx) 结合时. 然而,需要更多的研究才能充分了解标准MCC疗法的安全性和有效性.

科学领域:

在瘤学瘤学.
辐射瘤学辐射瘤学
手术瘤学手术瘤学

背景情况:

默克尔细胞癌 (MCC) 是一种罕见且具有攻击性的皮肤癌.
关于早期MCC的最佳治疗策略缺乏共识,包括手术 (SRx),放射治疗 (RTx) 和化疗 (CTx).

研究的目的:

系统地审查和分析现有的关于标准疗法对早期MCC有效性的文献.
评估辅助放射治疗对生存和复发结果的影响.

主要方法:

1972年至2023年发表的随机和非随机研究的系统审查和元分析.
包括报告总生存率 (OS),局部复发率 (LR),区域复发率 (RR),疾病特异性生存率 (DSS) 和无疾病生存率 (DFS) 的研究.
使用反变异异质模型将危险比率 (HRs) 聚合在一起.

主要成果:

包括49项研究,共有46,215名参与者.
与SRx相结合的辅助RTx显示,与单独SRx相比,在统计学上显著改善了OS (HR=0.78),尽管存在显著的异质性.
辅助RTx显著改善了DFS (HR=0.35) 并对本地而不是区域MCC更有效. 放射治疗剂量被确定为一个混因素.

结论:

辅助性RTx改善了早期MCC的生存和复发结果.
标准MCC疗法的安全性和有效性需要进一步研究.
对比疗效研究对于优化MCC治疗策略至关重要.

关键词:

梅克尔细胞癌瘤是什么?没有疾病的生存率.疾病特异性生存率疾病特异性生存率当地复发局部复发这是一个元分析.总体存活率总体存活率区域性复发地区性复发

更多相关视频

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

相关概念视频

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...